Business Context and Reporting Period
Company: ICU Medical, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2003
Business Overview: The company develops, manufactures, and sells disposable medical connection products, primarily proprietary safe medical connection devices for intravenous (I.V.) therapy and blood collection needles (Punctur-Guard). Key customers include Abbott Laboratories and independent distributors.
Key Financial Metrics
| Metric (in thousands) | Q3 2003 | Q3 2002 | 9 Months 2003 | 9 Months 2002 |
|---|---|---|---|---|
| Total Revenue | $25,524 | $20,105 | $77,583 | $63,678 |
| Net Sales | $25,016 | $20,105 | $73,616 | $63,678 |
| Gross Profit | $12,278 | $11,564 | $42,165 | $37,249 |
| Gross Margin % | 47.0% | 58.0% | 52.0% | 59.0% |
| Net Income | $4,175 | $4,276 | $15,144 | $13,797 |
| Diluted EPS | $0.28 | $0.28 | $1.00 | $0.90 |
| Cash & Liquid Investments | $71,114 | $88,465 | $71,114 | $88,465 |
| Working Capital | $91,751 | $102,564 | $91,751 | $102,564 |
Note: Working Capital calculated as Total Current Assets ($101,043) minus Total Current Liabilities ($9,292) for 9/30/03.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 27% in Q3 2003 and 22% for the nine-month period compared to 2002. Growth was driven by a 62% increase in custom I.V. systems sales and the inclusion of Punctur-Guard sales following the Bio-Plexus acquisition.
- Customer Concentration: Abbott Laboratories accounted for 65% of Q3 2003 revenue. Sales to B. Braun Medical Inc. dropped to 1% in Q3 2003 from 11% in Q3 2002 due to the termination of the CLAVE supply agreement effective December 31, 2002.
- Margin Compression: Gross margin declined to 47% in Q3 2003 from 58% in Q3 2002. Management attributes this to temporary factors including unabsorbed overhead from new high-capacity molds and lower margins on Punctur-Guard products.
- Capital Allocation: The company spent $15.3 million on treasury stock repurchases in the first nine months of 2003. Additionally, $6.5 million was advanced in commercial loans via a subsidiary, ICU Finance, Inc.
Guidance, Outlook, and Risks
- Outlook: Management expects continued growth in CLAVE unit and dollar sales volume through the balance of 2003, particularly with Abbott and independent distributors. They anticipate a resumption of growth in international CLAVE sales in the first half of 2004.
- Margin Recovery: Gross margins are expected to improve as production volumes match new capacity and Punctur-Guard manufacturing efficiencies increase.
- Capital Expenditures: Estimated at $11.5 million for 2003, primarily for facility expansion in Mexico and new manufacturing equipment. 2004 spending is expected to be less than half of 2003 levels.
- Strategic Shifts: The company discontinued new lending activities in October 2003 but will honor existing commitments. They are actively pursuing patent litigation against B. Braun regarding the UltraSite connector.
- Risks: Significant dependence on Abbott (65% of revenue); potential price erosion due to competition; and the transition of manufacturing facilities in Italy and Connecticut.
Investor Verification Checklist
- Customer Concentration: Verify the stability of the Abbott Laboratories relationship, which represents the majority of revenue, especially in light of Abbott's announced spin-off of its Hospital Products Business.
- B. Braun Litigation: Monitor the status of the patent infringement lawsuit against B. Braun and the impact of the terminated supply agreement on long-term market share.
- Margin Trends: Track gross margin recovery in upcoming quarters to confirm that temporary overhead costs from capacity expansion are being absorbed.
- International Sales: Watch for the anticipated resumption of growth in international CLAVE sales in 2004, as current inventory levels at distributors are suppressing orders.
- Acquisition Integration: Assess the performance of the Bio-Plexus (Punctur-Guard) product line and the Italian manufacturing facility integration.